InMed Pharmaceuticals

INM

Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026 VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Mentari Therapeutics, Inc.) (NASDAQ: INM) ("Mentari" or the "Company") today announced the completion of the previously disclosed merger between the Company and the privately held Mentari Therapeutics, Inc. ("pre-merger Mentari"). The combined company will continue to operate under the name Mentari Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market at market open on Monday, November 9, 2026, under the name "Mentari Therapeutics, Inc.," the ticker symbol "MTRI" and the new CUSIP number 587157108.

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, subject to the satisfaction or waiver of the remaining closing conditions under the agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement"), among the Company, Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), Indigo Merger Sub Corp. and Indigo Merger Sub II, LLC, the Company's previously announced merger with Mentari (the "Merger") is expected to close on November 6, 2026. On the closing date and prior to the completion of the Merger, the Company expects to redomesticate from British Columbia, Canada to the State of Nevada.

Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, confirmed that, at its annual general and special meeting of shareholders held today (the "Meeting"), the matters put forward before shareholders for consideration and approval, as set out in the Company's proxy statement/prospectus and management information circular dated October 1, 2026 (the "Circular"), were voted upon by the Company's shareholders. A total of 3,630,088 common shares of the Company (each, a "Common Share"), representing approximately 66.08% of the Company's 5,493,735 issued and outstanding common shares, were represented in person or by proxy at the Meeting.

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update. The Company's full financial statements and related MD&A for the quarter ended September 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.

Vancouver, British Columbia--(Newsfile Corp. - November 2, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed merger (the "Merger") involving Mentari Therapeutics, Inc. ("Mentari"), the Company expects to consolidate all of its issued and outstanding Common Shares on the basis of one (1) post-consolidation Common Share for each ten (10) pre-consolidation Common Shares (the "Consolidation"). The Consolidation was approved by the Company's Board of Directors in accordance with the Company's Articles and the Business Corporations Act (British Columbia) (the "BCBCA") and does not require the approval of shareholders of the Company; however, the Company will only proceed with the Consolidation if the approval of shareholders of the Company at the annual general and special meeting of the Company scheduled to be held on November 4, 2026 (the "Meeting") is obtained in respect of Proposal No.

Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed merger (the "Merger") involving Mentari Therapeutics, Inc. ("Mentari"), it has fixed the close of business on November 5, 2026 (the "CVR Distribution Record Date") as the record date for the distribution of the contingent value rights (each, a "CVR") to InMed shareholders of record as of the CVR Distribution Record Date in connection with the Merger. The distribution of the CVRs is subject to and conditional upon the approval of shareholders of the Company at the annual general and special meeting of the Company scheduled to be held on November 4, 2026 (the "Meeting") of Proposal No.

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026, was below the minimum shareholders' equity of $2,500,000 required for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1). The decline in the Company's shareholders' equity is attributable largely to transaction-related expenses accrued in connection with the Company's previously announced Agreement and Plan of Merger and Reorganization dated May 19, 2026 (as amended, the "Merger Agreement") entered into with Mentari Therapeutics, Inc. ("Mentari"), pursuant to which, among other things, the Company will merge with Mentari (the "Merger").

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.

Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.

WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors.